A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action.
By inhibiting a certain protein, the researchers were able to reduce the signals that trigger an inflammation. The study is published in Science and was done in collaboration with the University of Texas Medical Branch, Uppsala University and Stockholm University.
“We’ve developed a new drug molecule that inhibits inflammation,” says Professor Thomas Helleday, at the Department of Oncology-Pathology, Karolinska Institutet, Sweden, who co-led the study with Dr Torkild Visnes and Dr Armando Cázares-Körner. “It acts on a protein that we believe is a general mechanism for how inflammation arises in cells.”
The discovery is the result of many years of research by Thomas Helleday’s group on how DNA is repaired by the body. One of the objectives has been to fight cancer by targeting damage to the tumour cells’ DNA. Several breakthroughs have already been reported, which have led, amongst other things, to a new treatment for congenital breast and ovarian cancer using so-called PARP inhibitors, which has been available for some years.
Trials on mice
It was when developing a new molecule for inhibiting the enzyme that repairs oxygen damage to DNA that the researchers found, to their surprise, that it also dampened inflammation. It turned out that the enzyme OGG1, apart from repairing DNA, also triggers inflammation.
The inhibitor blocks the release of inflammatory proteins, such as TNF alpha. In trials on mice with acute pulmonary disease, the researchers succeeded in dampening the inflammation.
“This discovery could give rise to a new treatment for a very serious condition,” says Professor Helleday. “We’ll now be developing our OGG1 inhibitor and examining whether it can lead to new treatments for inflammatory diseases in order to cure or relieve diseases such as sepsis, COPD and severe asthma.”
The discovery was made in collaboration with Professor Istvan Boldogh from the University of Texas Medical Branch, USA.
The repair pathway on which OGG1 operates was discovered by Tomas Lindahl at Karolinska Institutet in the 1970s, an achievement that earned him the Nobel Prize in Chemistry in 2015.
Collaboration between several universities
The study was a collaboration between Karolinska Institutet, Uppsala University and Stockholm University in Sweden and the University of Texas Medical Branch, USA.
Learn more: New inflammation inhibitor discovered
The Latest on: Anti-inflammatory drug
via Google News
The Latest on: Anti-inflammatory drug
- Artificial intelligence reveals current drugs that may help combat Alzheimer's diseaseon March 4, 2021 at 11:32 am
New treatments for Alzheimer's disease are desperately needed, but numerous clinical trials of investigational drugs have failed to generate promising options. Now a team at Massachusetts General ...
- AI-based method for repurposing existing drugs into potential treatments for Alzheimer'son March 4, 2021 at 8:49 am
New treatments for Alzheimer's disease are desperately needed, but numerous clinical trials of investigational drugs have failed to generate promising options.
- Ivermectin drug is not effective at treating mild COVID-19, study findson March 4, 2021 at 8:43 am
Ivermectin, a drug normally used to treat parasites including lice and rabies, did not seem to have a significant impact and improve the symptoms of patients with COVID-19.
- Scientists will test whether gout drug helps beat Covid symptomson March 3, 2021 at 9:31 am
Oxford University researchers have begun trials on 30p pill colchicine today to examine whether it can reduce recovery time from Covid and prevent the need for hospital admission.
- Second UK study to test gout drug as potential COVID-19 treatmenton March 3, 2021 at 4:40 am
A large British study looking into potential early-stage COVID-19 treatments will begin testing gout medication colchicine and has widened enrolment criteria for the arm of the trial, University of ...
- Non-steroidal anti-inflammatory agent use may not be associated with mortality of coronavirus disease 19on March 2, 2021 at 4:00 pm
Non-steroidal anti-inflammatory drugs (NSAIDs) have been widely used in patients with respiratory infection, but their safety in coronavirus disease 19 (Covid-19) patients has not been fully ...
- This One Drug Could Help You Lose 10 Pounds, Says New Studyon March 2, 2021 at 10:00 am
According to a new study published in The New England Journal of Medicine, the drug semaglutide helped 35% of participants lose 20% of their weight.
- Well-known spasmolytic drug can suppress inflammatory response in astrocyteson February 26, 2021 at 7:52 pm
Biologists from RUDN University confirmed that a well-known spasmolytic drug called hymecromone can suppress the inflammatory response in astrocytes, important glial cells of the central nervous ...
- Ophthalmology Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030on February 25, 2021 at 8:01 am
Major companies in the ophthalmology drugs market include Novartis AG; F. Hoffmann-La Roche Ltd; Allergan Plc; Valeant Pharmaceuticals Intl Inc and Bayer AG. The global ophthalmology drugs market is ...
via Bing News